By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Praxis Precision Medicines, Inc. insiders have only been selling lately: four insiders reduced their stakes by about $44.3 million of stock over 12 months, with no open-market purchases.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
Big money check: 309 institutions held PRAX as of Q2 2026, and more funds bought than sold. Members of Congress reported 1 trade in PRAX over the past two years (one member). Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
Are insiders buying or selling PRAX stock?
In the last 12 months Praxis Precision Medicines, Inc. insiders made open-market purchases worth about $0 and sales worth about $44.3 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in PRAX?
The most recent open-market insider trade in PRAX was filed on 2026-06-26.
How many institutions own PRAX?
309 investment managers reported holding PRAX in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded PRAX?
Yes. Members of Congress reported 1 trades in PRAX over the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).